Sage Group plc (SGE) Ordinary 1 4/77p Sell: 704.20p Buy: 704.80p 12.80p (1.85%) FTSE 100: 0.09%
Full Answer
What is the ticker code for Sage Group plc?
Sage Group Plc Ord 1 4/77P is listed on the London Stock Exchange, trading with ticker code SGE. It has a market capitalisation of £7,077 m, with approximately 1,018 m shares in issue.
Who buys Sage stock?
SAGE stock was acquired by a variety of institutional investors in the last quarter, including Cooper Financial Group, and State of Alaska Department of Revenue. Company insiders that have bought Sage Therapeutics stock in the last two years include Albert Robichaud, Barry E Greene, James M Frates, and Jeffrey M Jonas.
What is Sage Group's market capitalisation?
It has a market capitalisation of £7,077 m, with approximately 1,018 m shares in issue. Over the last year, Sage Group share price has been traded in a range of 306.2, hitting a high of 862.2, and a low of 556.
What are analysts'1-year price targets for SAGE Therapeutics'stock?
17 Wall Street analysts have issued 1-year price objectives for Sage Therapeutics' stock. Their forecasts range from $44.00 to $100.00. On average, they anticipate Sage Therapeutics' share price to reach $70.63 in the next twelve months.
See more
Is Sage a UK company?
The Sage Group plc, commonly known as Sage, is a British multinational enterprise software company based in Newcastle upon Tyne, England.
Is Sage publicly traded?
The Sage Group plc, formed in 1981, was floated on the London Stock Exchange in 1989 and now employs more than 13,500 people and supports more than 6 million customers worldwide.
What company owns Sage?
Sage GroupSage Intacct, Inc is an American provider of cloud-based Financial management and services available in five regions around the globe -- including the United States, Canada, the UK, Australia, and South Africa....Sage Intacct.FormerlyIntacct CorporationParentSage GroupWebsitewww.sageintacct.com8 more rows
How many customers does Sage have in the UK?
600,000 customersSage is a brand that we all know. It is one of the most iconic British companies and has more than 600,000 customers in the UK – more than any other tech company by far.
Is Sage a buy or sell?
Out of 11 analysts, 2 (18.18%) are recommending SAGE as a Strong Buy, 2 (18.18%) are recommending SAGE as a Buy, 7 (63.64%) are recommending SAGE as a Hold, 0 (0%) are recommending SAGE as a Sell, and 0 (0%) are recommending SAGE as a Strong Sell. What is SAGE's earnings growth forecast for 2022-2024?
What is Sage revenue?
1.846 billion GBP (2021)Sage Group / Revenue
Is Sage owned by Oracle?
Acquisitions by Sage and Oracle NetSuite was acquired by Oracle in 2016 for $9.3 billion and is now run as a separate business unit within the company. Oracle's backing enabled NetSuite to more quickly expand its international operations and open new data centers based on the powerful Oracle Cloud Infrastructure.
Who are sages competitors?
Sage's top competitors include SAP Deutschland, Advanced, Pegasystems, Intuit, Xero and Oracle Financial Services Software. Sage Group is a company that provides business management software and services for companies to manage their operations.
How many customers does Sage Software have?
In 1991, Sage entered tothe U.S. market, and today it operates in more than 20 countries, employs 12,000 people, and serves more than 2 million customers. Hare was named chief financial officer in 2014 and took over as CEO in 2018.
Why are Sage shares falling?
The firm said this was due to a decline in recurring business from existing customers, and a decrease in price on new contract licence. Sage said sales growth was below management's expectations, and as a result, it revised its sales forecast for sales growth down to 7% for the full year, down from 8%.
What do Sage company do?
Sage is the market leader for integrated accounting, payroll, and payment systems, supporting the ambition of the world's entrepreneurs. Like many of the businesses we serve, Sage began as a small business and has grown beyond what seemed imaginable.
Is Sage Accounting any good?
Sage Business Cloud Accounting Verdict Sage Business Cloud Accounting is a great option for small businesses. The powerful software is intuitive and easy to use, while the best-in-class 24/7 customer support means there's always someone available if you need help.
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sage Therapeutics (SAGE) Depression Drug Meets Goal, Stock Down
Sage Therapeutics (SAGE) and Biogen's (BIIB) depression candidate, zuranolone given along with antidepressants improves depressive symptoms in a phase III study. Questions remain about the durability of the drug.
Why Sage Therapeutics Stock Is Crashing Today
The late-stage trial results for the company's major depressive disorder drug aren't impressing investors today.
Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) said zuranolone combined with a standard of care antidepressant met the primary goal of showing rapid and significant reduction in depressive symptoms in a late-stage study.
Sage's depression drug improves symptoms, but durability concerns sink shares
Sage Therapeutics Inc's drug helped improve depressive symptoms after three days in a late-stage study, but investor concerns over how long the treatment's effect would last sent the drug developer's shares down 17% on Wednesday.
UPDATE 2-Sage's depression drug meets main goal in late-stage study
Sage Therapeutics Inc said on Wednesday its drug along with an antidepressant helped improve depressive symptoms after three days in a late-stage study, paving way for the drug developer to submit data for U.S. approval this year.
Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD
CAMBRIDGE, Mass., February 16, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc.
When will Sage Therapeutics release its earnings?
Sage Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021. View our earnings forecast for Sage Therapeutics.
How much does Sage Therapeutics make?
Sage Therapeutics has a market capitalization of $2.82 billion and generates $1.11 billion in revenue each year. The biopharmaceutical company earns $606.07 million in net income (profit) each year or ($9.47) on an earnings per share basis.
Who bought Sage Therapeutics?
Company insiders that have bought Sage Therapeutics stock in the last two years include Albert Robichaud, Barry E Greene, James M Frates, and Jeffrey M Jonas. View insider buying and selling activity for Sage Therapeutics or or view top insider-buying stocks.
